Showing results (4051-4060 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|April 3, 2023
Efficacy and Dose-Response Relationship of Stereotactic Body Radiotherapy for Abdominal Lymph Node Metastases from Hepatocellular CarcinomaYuting Wang, Qiaoqiao Li, Li Zhang, et al.
The Oncologist|April 4, 2023
Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD StudyMarta Miarons, Alba Manzaneque Gordón, Pau Riera, et al.
The Oncologist|April 6, 2023
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast CancerYuan Yuan, Susan E Yost, Yujie Cui, et al.
The Oncologist|April 6, 2021
Patients' and Oncologists' Knowledge and Expectations Regarding Tumor Multigene Next-Generation Sequencing: A Narrative ReviewMelika Shirdarreh, Orly Aziza, Rossanna C Pezo, et al.
The Oncologist|April 25, 2021
HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric AdenocarcinomaXiao-Dong Jiao, Ke Liu, Ying Wu, et al.
The Oncologist|April 25, 2021
Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the LiteratureMichael May, Alexander G Raufi, Sina Sadeghi, et al.
The Oncologist|April 24, 2021
Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell CarcinomaWencheng Zhang, Cihui Yan, Xuan Gao, et al.
The Oncologist|August 12, 2025
Patients' and caregivers' perspectives on preparedness for and experience with chimeric antigen receptor-T cell therapyAnna Barata, Bridget Coffey, Hermioni L Amonoo, et al.
The Oncologist|August 12, 2025
Impact of Treatment Patterns and Sequencing on Clinical and Economic Outcomes in Patients with Metastatic Urothelial Cancer: IMPACT UC II StudyMehmet A Bilen, Brandon Diessner, John White, et al.
The Oncologist|August 12, 2025
Treatment, outcomes, and resource utilization among patients with metastatic breast and advanced epithelial ovarian cancer, by BRCA1/2 and HRD statusGiovanna I Cruz, Kaitlyn L Kane, Rayna K Matsuno, et al.
Pageof 571